Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted involved-site radiotherapy plus Gazyvaro for early-stage nodal follicular lymphoma
2016-002059-89Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in follicular lymphoma (FL), sponsored by Heidelberg University. Primary endpoint: Metabolic complete response. Started Jun 2017; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2016-002059-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002059-89.